Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of tepotinib in subjects with advanced adenocarcinoma of the lung harboring the MET exon 14 (METex14) skipping alterations, as per objective response (confirmed complete response [CR] or partial response [PR]) determined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, based on independent review.
Critère d'inclusion
- Stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations